On October 16, 2025, Thermo Fisher Scientific announced a collaboration with OpenAI to integrate AI capabilities into the areas of drug development and clinical trials. OpenAI's APIs will be integrated into drug design processes, analyze trial failures, and improve internal research efficiency. The intended benefit is to reduce time and cost in the production of new therapies and drugs. Its importance lies in accelerating the path from idea to actual drug using AI.
Thermo Fisher collaborates with OpenAI to accelerate medical research.
